Search - tctmd.com

Displaying 41 - 60 of 183

Sort: Relevancy | Date

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation ACC 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

April 04, 2022

Presentation ESC 2021

Influenza Vaccination after Myocardial Infarction - a randomized, double-blind, placebo-controlled, multicenter trial

Presenter: Ole Fröbert

August 31, 2021

Presentation ACC 2020

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Presenter: Frederick Raal

March 30, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Presentation ACC 2020

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Presenter: William Hiatt

March 29, 2020

Presentation AHA 2019

Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: The EVAPORATE Study

Presenter: Matthew Budoff

November 18, 2019

Presentation

Dobutamine Stress Echo Ischemia a Predictor of PCI Efficacy in Stable CAD

November 14, 2019

Presentation ESC 2019

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

Presenter: Deepak Bhatt

September 01, 2019

Presentation

RAS Inhibition Following TAVR

July 29, 2019

Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Presentation ACC 2019

Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Presenter: Marco Valgimigli

March 18, 2019

Presentation ACC 2019

First Randomized Human Experience with a Ticagrelor Reversal Agent

Presenter: Deepak L. Bhatt

March 18, 2019

Presentation JIM 2019

Log-linear association per unit change in LDL-C and the risk of CV disease-a statin tale

Presenter: Bernardo Cortese

February 15, 2019

Presentation JIM 2019

GP IIb/IIIa inhibitors are still the best option

Presenter: Alberto Menozzi

February 15, 2019

Presentation JIM 2019

Consider Low Dose RIVAROXABAN + SAPT

Presenter: Roxana Mehran

February 15, 2019

Presentation JIM 2019

Clinical case: Management of long-term antithrombotic therapy

Presenter: Giuseppe Tarantini

February 15, 2019

Presentation ISC 2019

Treatment of Factor Xa Inhibitor-Associated Bleeding with Andexanet Alfa: Full Results of ANNEXA-4

Presenter: Stuart J. Connolly

February 08, 2019

Presentation Controversies and Advances 2018

Updateon PCS K-9 Inhibition

Presenter: P.K. Shah

November 15, 2018

Advertisement

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Influenza Vaccination after Myocardial Infarction - a randomized, double-blind, placebo-controlled, multicenter trial

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: The EVAPORATE Study

Dobutamine Stress Echo Ischemia a Predictor of PCI Efficacy in Stable CAD

THEMIS: Ticagrelor Added to Aspirin in Patients with Stable Coronary Disease and Diabetes

RAS Inhibition Following TAVR

Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

First Randomized Human Experience with a Ticagrelor Reversal Agent

Log-linear association per unit change in LDL-C and the risk of CV disease-a statin tale

GP IIb/IIIa inhibitors are still the best option

Consider Low Dose RIVAROXABAN + SAPT

Clinical case: Management of long-term antithrombotic therapy

Treatment of Factor Xa Inhibitor-Associated Bleeding with Andexanet Alfa: Full Results of ANNEXA-4

Updateon PCS K-9 Inhibition

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content